Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (911-920 of 1,482) with videos related to

Pageof 149
Sort By:
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 27, 2021
Perspectives for systems biology in the management of tuberculosisIrina Kontsevaya, Christoph Lange, Patricia Comella-Del-Barrio, et al.
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Anesthesiology|June 22, 2019
Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor SignalingTony L Yaksh, Kelly A Eddinger, Shinichi Kokubu, et al.
Haematologica|September 2, 2018
Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemiaChi Young Ok, Sanam Loghavi, Dawen Sui, et al.
Journal of Hypertension|November 15, 2011
In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: a new drug target for hypertension?Antonella Liantonio, Gianluca Gramegna, Giulia M Camerino, et al.
American Journal of Hematology|April 26, 2021
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Gautam Borthakur, et al.
JNCI Cancer Spectrum|June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adultsAmy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Pageof 149

Showing results (911-920 of 1,482) with videos related to

Sort By:
Pageof 149
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 27, 2021
Perspectives for systems biology in the management of tuberculosisIrina Kontsevaya, Christoph Lange, Patricia Comella-Del-Barrio, et al.
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Anesthesiology|June 22, 2019
Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor SignalingTony L Yaksh, Kelly A Eddinger, Shinichi Kokubu, et al.
Haematologica|September 2, 2018
Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemiaChi Young Ok, Sanam Loghavi, Dawen Sui, et al.
Journal of Hypertension|November 15, 2011
In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: a new drug target for hypertension?Antonella Liantonio, Gianluca Gramegna, Giulia M Camerino, et al.
American Journal of Hematology|April 26, 2021
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Gautam Borthakur, et al.
JNCI Cancer Spectrum|June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adultsAmy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Pageof 149